Medical technology company iRhythm Technologies (NASDAQ: IRTC) will be announcing earnings results this Thursday after market hours. Here’s what to look for.

iRhythm beat analysts’ revenue expectations by 3.3% last quarter, reporting revenues of $158.7 million, up 20.3% year on year. It was a strong quarter for the company, with full-year revenue guidance beating analysts’ expectations.

Is iRhythm a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting iRhythm’s revenue to grow 17.5% year on year to $174 million, slowing from the 19.3% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.47 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. iRhythm has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.3% on average.

Looking at iRhythm’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 13.4%, beating analysts’ expectations by 3.7%, and Boston Scientific reported revenues up 22.8%, topping estimates by 3.4%. Boston Scientific traded up 2.9% following the results.

Read our full analysis of Penumbra’s results here and Boston Scientific’s results here.

Investors in the healthcare equipment and supplies segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. iRhythm is down 9.3% during the same time and is heading into earnings with an average analyst price target of $146.83 (compared to the current share price of $139.59).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.